Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app aims to ease pancreatic cancer treatment journey

NCT ID NCT07047807

First seen Apr 29, 2026 · Last updated Jun 23, 2026 · Updated 8 times

Summary

This study is testing a smartphone app called PDAC-PATHWAYS designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy (treatment before surgery). The app includes educational modules and tools to help patients cope. Researchers want to see if it's practical and acceptable to use, enrolling 50 patients from one hospital.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

digital informational and supportive care app

What this could lead to

If successful, this app could provide a practical way to help pancreatic cancer patients better manage their treatment journey.

What could go wrong

This is a small, early feasibility study with only 50 participants. The app may not improve outcomes or be widely adopted.

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.